Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Osteoclast differentiation and activation.

Boyle WJ, Simonet WS, Lacey DL.

Nature. 2003 May 15;423(6937):337-42. Review.

PMID:
12748652
2.

Bone resorption by osteoclasts.

Teitelbaum SL.

Science. 2000 Sep 1;289(5484):1504-8. Review.

PMID:
10968780
3.

Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands.

Horowitz MC, Xi Y, Wilson K, Kacena MA.

Cytokine Growth Factor Rev. 2001 Mar;12(1):9-18. Review.

PMID:
11312114
4.

RANKL-RANK signaling in osteoclastogenesis and bone disease.

Wada T, Nakashima T, Hiroshi N, Penninger JM.

Trends Mol Med. 2006 Jan;12(1):17-25. Epub 2005 Dec 13. Review.

PMID:
16356770
5.

Genetic regulation of osteoclast development and function.

Teitelbaum SL, Ross FP.

Nat Rev Genet. 2003 Aug;4(8):638-49. Review.

PMID:
12897775
6.

Signal transduction pathways regulating osteoclast differentiation and function.

Tanaka S, Nakamura I, Inoue J, Oda H, Nakamura K.

J Bone Miner Metab. 2003;21(3):123-33. Review. No abstract available.

PMID:
12720046
7.

Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.

Tanaka S, Nakamura K, Takahasi N, Suda T.

Immunol Rev. 2005 Dec;208:30-49. Review.

PMID:
16313339
8.

Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development.

Kong YY, Boyle WJ, Penninger JM.

Immunol Cell Biol. 1999 Apr;77(2):188-93. Review.

9.

Current topics in pharmacological research on bone metabolism: osteoclast differentiation regulated by glycosphingolipids.

Fukumoto S, Iwamoto T, Sakai E, Yuasa K, Fukumoto E, Yamada A, Hasegawa T, Nonaka K, Kato Y.

J Pharmacol Sci. 2006 Mar;100(3):195-200. Epub 2006 Mar 14. Review.

10.

Cell biology of the osteoclast.

Roodman GD.

Exp Hematol. 1999 Aug;27(8):1229-41. Review.

PMID:
10428500
11.

The mechanisms of estrogen regulation of bone resorption.

Riggs BL.

J Clin Invest. 2000 Nov;106(10):1203-4. Review. No abstract available.

12.

[Osteoporosis induced by immunosuppressant].

Fukunaga J, Sugahara T.

Nihon Rinsho. 2004 Feb;62 Suppl 2:740-3. Review. Japanese. No abstract available.

PMID:
15035219
13.

[Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].

Mochizuki S, Kiyokawa A, Nagayama Y.

Clin Calcium. 2005 Jan;15(1):35-42. Review. Japanese.

PMID:
15632471
15.

Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics.

Zaidi M, Blair HC, Moonga BS, Abe E, Huang CL.

J Bone Miner Res. 2003 Apr;18(4):599-609. Review.

16.
17.

Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.

Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC.

Calcif Tissue Int. 2004 Jan;74(1):103-6. Epub 2003 Oct 6. Review.

PMID:
14523602
18.

Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.

Blair JM, Zhou H, Seibel MJ, Dunstan CR.

Nat Clin Pract Oncol. 2006 Jan;3(1):41-9. Review.

PMID:
16407878
19.

Molecular control of bone remodeling and osteoporosis.

Kong YY, Penninger JM.

Exp Gerontol. 2000 Oct;35(8):947-56. Review.

PMID:
11121682
20.

RANKing intracellular signaling in osteoclasts.

Feng X.

IUBMB Life. 2005 Jun;57(6):389-95. Review.

Supplemental Content

Support Center